视网膜下抽液联合玻璃体内注射康柏西普和气体治疗息肉样脉络膜血管病变并发浆液性视网膜色素上皮脱离的疗效和安全性  

Efficacy and safety of subretinal fluid extraction combined with intravitreal injection of conbercept and gas in the treatment of polypoidal choroidal vasculopathy complicated with serous retinal pigment epithelium detachment

作　　者：徐恩沛 孙先勇 高荣玉 刘建东 李南 杨娟娟 XU Enpei;SUN Xianyong;GAO Rongyu;LIU Jiandong;LI Nan;YANG Juanjuan(Weifang Eye Hospital,Weifang 261041,Shandong Province,China)

机构地区：[1]潍坊眼科医院,山东省潍坊市261041

出　　处：《眼科新进展》2024年第3期208-212,共5页Recent Advances in Ophthalmology

基　　金：潍坊市软科学项目(编号:2020RKX176)。

摘　　要：目的探讨视网膜下抽液联合玻璃体内注射康柏西普和气体治疗息肉样脉络膜血管病变(PCV)并发浆液性视网膜色素上皮脱离(sPED)的疗效和安全性。方法选取2019年7月至2021年2月于潍坊眼科医院行视网膜下抽液联合玻璃体内注射康柏西普和气体治疗的PCV并发sPED患者共13例(13眼),所有患眼术前接受过至少3次(每月1次)的玻璃体内抗血管内皮生长因子(VEGF)(雷珠单抗)注射治疗,且治疗无效。检测术前和术后1周、1个月、3个月、6个月患者的最佳矫正视力(BCVA)、中央视网膜厚度(CRT)、黄斑中心凹PED高度及宽度变化,记录术中及术后并发症发生情况。结果术后1周患眼BCVA较术前好转,差异有统计学意义(Z=-3.237,P=0.001);术后1周、1个月、3个月、6个月患眼CRT均较术前变薄,差异均有统计学意义(Z=-3.180、-3.180、-3.110、-3.180,P=0.001、0.001、0.002、0.001);术后1周、1个月、3个月、6个月患眼PED高度和宽度均较术前下降,差异均有统计学意义(均为P<0.05)。术前13眼平均接受过(4.15±1.40)次玻璃体内注药(雷珠单抗)治疗,治疗时间为(5.92±3.95)个月(相当于每6周注射1次)。术后随访6个月内13眼平均接受了(2.31±1.97)次玻璃体内重复注射(康柏西普)治疗(相当于每10周注射1次)。偏相关分析结果显示,术后6个月时患眼BCVA提高量与CRT的降低量呈弱正相关(r=0.416,P=0.203);术后6个月时患眼BCVA提高量与PED高度和宽度的变化量无明显相关性(r=0.218、0.209,P=0.520、0.538)。术后1个月时,9眼出现PED复发或不同程度的视网膜神经上皮下积液,后期配合玻璃体内重复注射康柏西普治疗,PED均改善。术后6个月时,3眼黄斑中心凹下PED完全消失,视网膜解剖完全复位,1眼黄斑区视网膜仍存在活动性渗出。13眼术后随访期间均未出现全身及严重眼部并发症。结论视网膜下抽液联合玻璃体内注射康柏西普和气体治疗PCV并发sPED能够安全Objective To investigate the efficacy and safety of subretinal fluid extraction combined with intravitreal conbercept and gas injection in treating polypoidal choroidal vasculopathy(PCV)complicated with serous retinal pigment epithelium detachment(sPED).Methods From July 2019 to February 2021,13 patients(13 eyes)with PCV complicated with sPED who were treated with subretinal fluid extraction combined with intravitreal injection of conbercept and gas in the Weifang Eye Hospital were selected.All affected eyes received at least 3 times(once a month)of intravitreal anti-vascular endothelial growth factor(VEGF)(ranibizumab)injections before the surgery,and the treatment was ineffective.The changes in best corrected visual acuity(BCVA),central retinal thickness(CRT),macular foveal PED height and width before and 1 week,1 month,3 months and 6 months after the operation were observed,and the intraoperative and postoperative complications were recorded.Results The BCVA of the affected eyes 1 week after operation was better than that before operation,and the difference was statistically significant(Z=-3.237,P=0.001).The CRT of the affected eyes at 1 week,1 month,3 months and 6 months after the operation were thinner than that before the operation,and the difference was statistically significant(Z=-3.180,-3.180,-3.110 and-3.180,P=0.001,0.001,0.002 and 0.001).The height and width of PED at 1 week,1 month,3 months and 6 months after the operation were lower than those before the operation,and the differences were statistically significant(all P<0.05).Thirteen eyes received an average of(4.15±1.40)intravitreal injections(ranibizumab)before the surgery,and the treatment duration was(5.92±3.95)months(equivalent to one injection every 6 weeks).During the 6-month follow-up,13 eyes received an average of(2.31±1.97)intravitreal injections(conbercept)(equivalent to once every 10 weeks).Partial correlation analysis showed a weak positive correlation between the increase in BCVA and the decrease in CRT 6 months after operation(r=0.

关 键 词：视网膜下抽液 息肉样脉络膜血管病变 浆液性视网膜色素上皮脱离 血管内皮生长因子 

分 类 号：R774[医药卫生—眼科]